Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477056 · ClinicalTrials.gov registry record
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.
- Completed
- Registry status
- 366
- Enrollment target
- 1
- Study location
NCT05477056 is a study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by C2N Diagnostics. The registered enrollment target is 366 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05477056, a study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by C2N Diagnostics.
- COMPLETED
- Registry status
- 366 participants
- Enrollment target
- 1
- Study location
Study Summary
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.
Conditions Studied
Interventions
- OTHER PrecivityAD blood test
Study Locations (1)
Missouri
- C2N Diagnostics - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-10-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477056
The ClinicalTrials.gov registry entry for NCT05477056 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The listed sponsor is C2N Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which PrecivityAD blood test is the first listed.
NCT05477056 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05477056 about?
NCT05477056 is a clinical study titled "Quality Improvement PrecivityAD Clinician Survey (QUIP I)". There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzhei...
What is the current status of trial NCT05477056?
This trial is currently completed. The enrollment target is 366 participants. The study started on 2021-03-01. Estimated completion is 2022-10-06.
What conditions does trial NCT05477056 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline.
What interventions are being tested in trial NCT05477056?
The interventions under investigation include: PrecivityAD blood test (OTHER).
Who is sponsoring clinical trial NCT05477056?
This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05477056 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.